Financials and Corporate

Innate Pharma announces today its tentative financial and investor relations calendar for 2010. The Company also announces today the settlement and delivery of its capital increase reserved to...

The “Fonds Stratégique d’Investissement” (French sovereign fund) invested 11 million euros Novo Nordisk A/S and Alta Partners, two historical shareholders of the Company, also participated in the...

Turnover for the first nine months of 2009 amounted to 2.8 million euros As at September 30, 2009, cash, cash equivalents and current financial instruments amounted 30.5 million euros

During the General Shareholders’ Meeting which took place on June 23, 2009, the general meeting of Innate Pharma (the Company - Euronext Paris: FR0010331421 – IPH) has authorized the Executive Board...

Innate Pharma (the Company - Euronext Paris: FR0010331421 – IPH) announces today the signature of a liquidity agreement with NatIxis Securities. The agreement will be effective September 21, 2009, for...

Hervé Brailly, CEO of Innate Pharma, and Stéphane Boissel, Executive Vice President and Chief Financial Officer, will present the Company to the investors during the MIDCAP event in Paris Upon the...

Publication of important clinical data for IPH 1101 and IPH 2101, Innate Pharma’s two lead drug candidates. Increase in operational loss, explained notably by the contractual end of the R&D...

Innate Pharma held its annual general meeting on June 23, 2009 All proposed resolutions were voted according to management’s recommendations Mrs. Irina Staatz-Granzer joins the Supervisory Board as a...

Innate Pharma, Transgene, ImmunID, Inserm and the cancer hospital Centre Léon-Bérard announced the operational start of PLATINE, a joint immuno-monitoring platform.